Tue, March 15, 2011
Mon, March 14, 2011
[ Mon, Mar 14th 2011 ] - Market Wire
30 AM E.T.
Sun, March 13, 2011
Sat, March 12, 2011
Fri, March 11, 2011
[ Fri, Mar 11th 2011 ] - Market Wire
Covidien????????????????FDA??
Thu, March 10, 2011
Wed, March 9, 2011
Tue, March 8, 2011
Mon, March 7, 2011
Sat, March 5, 2011
Fri, March 4, 2011
Thu, March 3, 2011
Wed, March 2, 2011
[ Wed, Mar 02nd 2011 ] - Market Wire
BURCON AMENDS LETTER OF INTENT
Tue, March 1, 2011
Mon, February 28, 2011
Sun, February 27, 2011
Fri, February 25, 2011
Thu, February 24, 2011

Peregrine's Bavituximab HCV Abstract Accepted for Presentation at the 46th Annual Meeting of EASL


//health-fitness.news-articles.net/content/2011/ .. entation-at-the-46th-annual-meeting-of-easl.html
Published in Health and Fitness on Monday, March 7th 2011 at 5:10 GMT by Market Wire   Print publication without navigation


TUSTIN, CA--(Marketwire - March 7, 2011) - Peregrine Pharmaceuticals, Inc. (NASDAQ: [ PPHM ]), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that data from the company's Phase Ib dose escalation safety study of bavituximab in patients coinfected with chronic hepatitis C virus (HCV) and HIV has been accepted for presentation at the 46th annual meeting of the European Association for the Study of the Liver (EASL) taking place in Berlin, Germany from March 30 to April 3, 2011.

The abstract can be accessed through the EASL website [ http://www2.kenes.com/liver-congress/Pages/Home.aspx ]. In accordance with the EASL embargo policy, the accepted abstract titled "Escalating Repeat Dose Study of Bavituximab in Patients Co-infected with Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus" (poster 1239) will be presented in a poster session on Saturday, April 2, 2011.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ([ www.avidbio.com ]), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at [ www.peregrineinc.com ].


Publication Contributing Sources